Cathepsin-D和nm23在乳腺癌蒽环类新辅助化疗中疗效的预测价值  

Cathepsin-D and nm23 provide the predictive value of response to anthracycline-based neoadjuvant chemotherapy in breast cancer

作　　者：陈毅作[1,2] 陈灿铭[1,2] 费菲[1,2] 张家新[1,2] 陆劲松[1,2] 狄根红[1,2] 柳光宇[1,2] 杨文涛[1,3] 陆洪芬[1,3] 沈坤炜[1,2] 沈镇宙[1,2] 邵志敏[1,2] 吴炅[1,2] 

机构地区：[1]复旦大学附属肿瘤医院乳腺外科 [2]复旦大学上海医学院肿瘤学系乳腺外科,上海200032 [3]复旦大学上海医学院肿瘤学系病理科,上海200032

出　　处：《中国实用外科杂志》2010年第1期59-62,共4页Chinese Journal of Practical Surgery

摘　　要：目的探讨乳腺癌病人肿瘤组织中分子生物学标记物的表达与含蒽环类新辅助化疗有效率的关系。方法检测复旦大学附属肿瘤医院2000年1月至2006年8月173例乳腺癌新辅助化疗病人化疗术前或术后标本中ER、PR、Her-2/neu等15种分子标记物的表达情况,分析这些分子标记物的表达在新辅助化疗中的疗效预测价值。结果nm23或Cathepsin-D阴性病人化疗疗效显著优于阳性病人,多因素回归分析提示Cathepsin-D是独立的新辅助化疗疗效预测指标。结论Cathepsin-D可能作为乳腺癌新辅助化疗(蒽环类)敏感性的独立预测指标。Objective To investigate the predictive value of biological markers for responsiveness to anthracyline-based regimen in neoadjuvant systemic therapy. Methods Post-operative paraffin-embedded tumor samples from 173 breast cancer patients were examined for expression of ER, PR, Her-2/neu, and other 15 markers by immunohistochemistry, to analyze the predictive value of these biological markers for response to neoadjuvant chemotherapy. Results For the primary tumor, the clinical objective response was 66.47%, 29.48%SD,and 4.05% PD. Pathological complete response was found in 3 eases（1.73%）.Negative nm23, and loss of Cathepsin-D were significantly predictive for an effective response to anthraeyeline-based neoadjuvant chemotherapy. In multivariate logistic regression analysis, only the Cathepsin-D status was found for independent predictive value. Conclusion Loss of Cathepsin-D independently predicts the response to anthracyeline-based regimen.

关 键 词：乳腺癌 新辅助化疗 预测因子 免疫组织化学 

分 类 号：R6[医药卫生—外科学]